PI3K-mediated signalling in Glioblastoma

Glioblastoma, or Glioblastoma multiforme (GBM), is among the most malevolent and difficult to treat malignancies. The patients' life expectancy barely exceeds one year post-diagnosis, despite aggressive therapeutic intervention, consisting of maximal surgical removal, followed by courses of radio- and chemotherapy. Modulation of the PI3K/Akt/mTOR pathway, which exhibits high activity in almost 90% of all GBM, has long been considered a promising approach to enhance therapeutic efficacy; however, despite intensive research, clinical successes have so far been sparse. Here, we look at the effects of inhibiting PI3…